Recent Advances of SIRT1 and Implications in Chemotherapeutics Resistance in Cancer

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2021 Dec 7

PMID 34873458

Citations 27

Authors

Neelum Aziz Yousafzai

Hongchuan Jin

Mujib Ullah

Xian Wang

Affiliations

Soon will be listed here.

Abstract

Cancer is a big group of diseases and one of the leading causes of mortality worldwide. Despite enormous studies and efforts are being carried out in understanding the cancer and developing drugs against tumorigenesis, drug resistance is the main obstacle in cancer treatments. Chemotherapeutic treatment is an important part of cancer treatment and drug resistance is getting gradually multidimensional with the advancement of studies in cancer. The underlying mechanisms of drug resistance are largely unknown. Sirtuin1 (SIRT1) is a type of the Class III histone deacetylase family that is distinctively dependent on nicotinamide adenine dinucleotide (NAD+) for catalysis reaction. SIRT1 is a molecule which upon upregulation directly influences tumor progression, metastasis, tumor cell apoptosis, autophagy, DNA repair, as well as other interlinked tumorigenesis mechanism. It is involved in drug metabolism, apoptosis, DNA damage, DNA repair, and autophagy, which are key hallmarks of drug resistance and may contribute to multidrug resistance. Thus, understanding the role of SIRT1 in drug resistance could be important. This study focuses on the SIRT1 based mechanisms that might be a potential underlying approach in the development of cancer drug resistance and could be a potential target for drug development.

Citing Articles

Global requirements for manufacturing and validation of clinical grade extracellular vesicles.

Thakur A, Rai D J Liq Biopsy. 2025; 6:100278.

PMID: 40027307 PMC: 11863704. DOI: 10.1016/j.jlb.2024.100278.

Role of Nicotinamide in the Pathogenesis of Actinic Keratosis: Implications for NAD/SIRT1 Pathway.

Belardi R, Pacifici F, Cosio T, Lambiase S, Shumak R, Artosi F Biomolecules. 2025; 14(12.

PMID: 39766219 PMC: 11673244. DOI: 10.3390/biom14121512.

The role of SIRT1 in autophagy and drug resistance: unveiling new targets and potential biomarkers in cancer therapy.

Tang Y, Ju W, Liu Y, Deng Q Front Pharmacol. 2024; 15:1469830.

PMID: 39403142 PMC: 11471651. DOI: 10.3389/fphar.2024.1469830.

SIRT1-mediated deacetylation of FOXO3 enhances mitophagy and drives hormone resistance in endometrial cancer.

Wei X, Xiong X, Wang P, Zhang S, Peng D Mol Med. 2024; 30(1):147.

PMID: 39266959 PMC: 11391609. DOI: 10.1186/s10020-024-00915-7.

Sirtuin1 (sirt1) regulates the glycolysis pathway and decreases cisplatin chemotherapeutic sensitivity to esophageal squamous cell carcinoma.

Yang X, Li S, Xu C, Liu S, Zhang X, Lian B Cancer Biol Ther. 2024; 25(1):2365449.

PMID: 38865161 PMC: 11174053. DOI: 10.1080/15384047.2024.2365449.

References

Jang J, Huh Y, Cho H, Lee B, Park J, Hwang D . SIRT1 Enhances the Survival of Human Embryonic Stem Cells by Promoting DNA Repair. Stem Cell Reports. 2017; 9(2):629-641. PMC: 5549766. DOI: 10.1016/j.stemcr.2017.06.001. View

Yousafzai N, Zhou Q, Xu W, Shi Q, Xu J, Feng L . SIRT1 deacetylated and stabilized XRCC1 to promote chemoresistance in lung cancer. Cell Death Dis. 2019; 10(5):363. PMC: 6494911. DOI: 10.1038/s41419-019-1592-3. View

Saunders L, Verdin E . Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene. 2007; 26(37):5489-504. DOI: 10.1038/sj.onc.1210616. View

Ullah M, Akbar A, Thakor A . An emerging role of CD9 in stemness and chemoresistance. Oncotarget. 2019; 10(40):4000-4001. PMC: 6592292. DOI: 10.18632/oncotarget.27021. View

Milne J, Lambert P, Schenk S, Carney D, Smith J, Gagne D . Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007; 450(7170):712-6. PMC: 2753457. DOI: 10.1038/nature06261. View

Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-81. DOI: 10.1038/nature03579. View

Ullah M, Ng N, Concepcion W, Thakor A . Emerging role of stem cell-derived extracellular microRNAs in age-associated human diseases and in different therapies of longevity. Ageing Res Rev. 2019; 57:100979. DOI: 10.1016/j.arr.2019.100979. View

Chen S, Dai Y, Harada H, Dent P, Grant S . Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 2007; 67(2):782-91. DOI: 10.1158/0008-5472.CAN-06-3964. View

Xiong H, Ni Z, Jiang S, Li X, He J, Gong W . LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene. 2017; 36(25):3528-3540. DOI: 10.1038/onc.2016.521. View

10.

Liu H, Zhang S, Liu C, Wu J, Wang Y, Yuan L . Resveratrol Ameliorates Microcystin-LR-Induced Testis Germ Cell Apoptosis in Rats via SIRT1 Signaling Pathway Activation. Toxins (Basel). 2018; 10(6). PMC: 6024601. DOI: 10.3390/toxins10060235. View

11.

Yuan H, Wang Z, Gao C, Chen W, Huang Q, Yee J . BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia. J Biol Chem. 2009; 285(7):5085-96. PMC: 2836111. DOI: 10.1074/jbc.M109.039206. View

12.

Wang C, Chen L, Hou X, Li Z, Kabra N, Ma Y . Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol. 2006; 8(9):1025-31. DOI: 10.1038/ncb1468. View

13.

Jin Y, Cao Q, Chen C, Du X, Jin B, Pan J . Tenovin-6-mediated inhibition of SIRT1/2 induces apoptosis in acute lymphoblastic leukemia (ALL) cells and eliminates ALL stem/progenitor cells. BMC Cancer. 2015; 15:226. PMC: 4394409. DOI: 10.1186/s12885-015-1282-1. View

14.

Yu W, Li L, Wang G, Zhang W, Xu J, Liang A . KU70 Inhibition Impairs Both Non-Homologous End Joining and Homologous Recombination DNA Damage Repair Through SHP-1 Induced Dephosphorylation of SIRT1 in T-Cell Acute Lymphoblastic Leukemia (T-ALL) [corrected]. Cell Physiol Biochem. 2018; 49(6):2111-2123. DOI: 10.1159/000493815. View

15.

Jarrett S, Carter K, Bautista R, He D, Wang C, DOrazio J . Sirtuin 1-mediated deacetylation of XPA DNA repair protein enhances its interaction with ATR protein and promotes cAMP-induced DNA repair of UV damage. J Biol Chem. 2018; 293(49):19025-19037. PMC: 6295715. DOI: 10.1074/jbc.RA118.003940. View

16.

Jung-Hynes B, Schmit T, Reagan-Shaw S, Siddiqui I, Mukhtar H, Ahmad N . Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model. J Pineal Res. 2010; 50(2):140-9. PMC: 3052633. DOI: 10.1111/j.1600-079X.2010.00823.x. View

17.

Arlt A, Muerkoster S, Schafer H . Targeting apoptosis pathways in pancreatic cancer. Cancer Lett. 2010; 332(2):346-58. DOI: 10.1016/j.canlet.2010.10.015. View

18.

Druker B, Guilhot F, OBrien S, Gathmann I, Kantarjian H, Gattermann N . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23):2408-17. DOI: 10.1056/NEJMoa062867. View

19.

Lambert G, Estevez-Salmeron L, Oh S, Liao D, Emerson B, Tlsty T . An analogy between the evolution of drug resistance in bacterial communities and malignant tissues. Nat Rev Cancer. 2011; 11(5):375-82. PMC: 3488437. DOI: 10.1038/nrc3039. View

20.

Brunet A, Sweeney L, Sturgill J, Chua K, Greer P, Lin Y . Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004; 303(5666):2011-5. DOI: 10.1126/science.1094637. View